drugset / Trial / NCT00566852

Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

NCT00566852

RandomizedParallel-groupDouble-blindSupportive care

Summary

RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy. PURPOSE: This randomized phase III trial is studying memantine to see how well it works compared to a placebo in preventing side effects caused by whole-brain radiation therapy in patients with brain metastases from solid tumors.

Timeline

Start
2008-03
Primary completion
2011-04
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 10 mg Oral